Treatment of Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor Results in Improved Event-Free Survival

BACKGROUND: Acute myelogenous leukemia (AML) associated with core binding factor abnormalities (CBF) is the type of leukemia most responsive to cytarabine (ara-C) therapy and is of relative favorable prognosis. In vitro and ex vivo observations suggest that increases in intra-cellular ara-C levels i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Borthakur, Gautam, Kantarjian, Hagop, Wang, Xuemei, Plunkett, William K., Gandhi, Varsha V, Faderl, Stefan, Garcia-Manero, Guillermo, Ravandi, Farhad, Pierce, Sherry, Estey, Elihu H.
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126078/
https://ncbi.nlm.nih.gov/pubmed/18932257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23927
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares